In the present study, we added sitagliptin or voglibose to combined metformin and insulin therapy for treating newly diagnosed T2DM patients with HbA1c≥9.0% and/or FPG≥11.1 mmol/L. The gene discussed is INS; the disease is type 2 diabetes mellitus.